Hybridoma App Note – Restoring high-titer antibody production

Scientists at a biotechnology company observed antibody titers decreasing over time in a commercial hybridoma line, rendering the cell line unsuitable for continued use.

Time-course imaging and immunofluorescent reporting of antibody secretion revealed that only 0.3% of the hybridoma population was secreting detectable antibody.

Using CellRaftA microscale polystyrene growth surface within an array used to spatially segregate cells/colonies while maintaining shared media access, enabling imaging over time and targeted isolation. Technology, antibody titer was recovered to levels that qualified for commercial use in less than one month from single cell seeding to characterized cell banking.